Nathan Wong/LinkedIn
Feb 1, 2026, 11:24
Nathan Wong on Economic Benefits of Inclisiran for LDL-C Control
Nathan Wong, Professor and Director, Heart Disease Prevention Program, Division of Cardiology, UC Irvine, shared on LinkedIn:
”Our latest paper in JACC Journals projects approximately 20 million US adults with inadequately controlled LDL-C on statins could benefit from inclisiran treatment, preventing more than 1.6 million ASCVD events over 10 years.”
Read the full article here.
Article: Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
Authors: Nathan Wong, Hridhay Karthikeyan, Wenjun Fan, Batul Electricwala
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation